-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Article source: Medical Rubik's Cube Info
On November 8, Gerry Pharmaceuticals announced that its subsidiary and Corning Jerry had signed an exclusive global development agreement for ASC22 (Envolimab) to treat all viral diseases including hepatitis B outside of Greater China
Under the terms of the agreement, Corning granted Jerry song ceremony outside Greater China and developed exclusive worldwide commercialization rights and interests of ASC22, indications for all viral diseases, including hepatitis B, including
On January 14, 2019, Gale and Corning Jerry jointly announced that the two parties have reached an exclusive development agreement for ASC22 in Greater China
On October 12 this year, Gallite Pharmaceuticals announced that it will orally report the results of the ASC22 chronic hepatitis B phase IIa study at the 2021 American Association for the Study of Liver Diseases (AASLD) annual meeting
Currently, ASC22 is undergoing a phase IIb clinical trial in China
Note: The original text has been deleted